DK0994863T3 - Krystalmodifikation af 1-(2,6-difluorbenzyl)-1H-1,2,3-triazol-4-carboxamid og dets anvendelse som antiepileptisk middel - Google Patents

Krystalmodifikation af 1-(2,6-difluorbenzyl)-1H-1,2,3-triazol-4-carboxamid og dets anvendelse som antiepileptisk middel

Info

Publication number
DK0994863T3
DK0994863T3 DK98934929T DK98934929T DK0994863T3 DK 0994863 T3 DK0994863 T3 DK 0994863T3 DK 98934929 T DK98934929 T DK 98934929T DK 98934929 T DK98934929 T DK 98934929T DK 0994863 T3 DK0994863 T3 DK 0994863T3
Authority
DK
Denmark
Prior art keywords
difluorobenzyl
carboxamide
triazole
crystal modification
antiepileptic agent
Prior art date
Application number
DK98934929T
Other languages
Danish (da)
English (en)
Inventor
Robert Portmann
Urs Christoph Hofmeier
Andreas Burkhard
Walter Scherrer
Martin Szelagiewicz
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=4209650&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0994863(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Application granted granted Critical
Publication of DK0994863T3 publication Critical patent/DK0994863T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
DK98934929T 1997-06-10 1998-06-08 Krystalmodifikation af 1-(2,6-difluorbenzyl)-1H-1,2,3-triazol-4-carboxamid og dets anvendelse som antiepileptisk middel DK0994863T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CH140497 1997-06-10
PCT/EP1998/003427 WO1998056772A1 (en) 1997-06-10 1998-06-08 Crystal modification of 1-(2,6-difluorobenzyl)-1h-1,2,3--triazole-4-carboxamide and its use as antiepileptic

Publications (1)

Publication Number Publication Date
DK0994863T3 true DK0994863T3 (da) 2003-05-26

Family

ID=4209650

Family Applications (2)

Application Number Title Priority Date Filing Date
DK98934929T DK0994863T3 (da) 1997-06-10 1998-06-08 Krystalmodifikation af 1-(2,6-difluorbenzyl)-1H-1,2,3-triazol-4-carboxamid og dets anvendelse som antiepileptisk middel
DK98934930T DK0994864T3 (da) 1997-06-10 1998-06-08 Krystalmodificering af 1-(2,6-difluorbenzyl)-1H-1,2,3-triazol-4-carboxamid og dets anvendelse som antiepileptikum

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK98934930T DK0994864T3 (da) 1997-06-10 1998-06-08 Krystalmodificering af 1-(2,6-difluorbenzyl)-1H-1,2,3-triazol-4-carboxamid og dets anvendelse som antiepileptikum

Country Status (36)

Country Link
US (6) US6740669B1 (enrdf_load_stackoverflow)
EP (2) EP0994864B1 (enrdf_load_stackoverflow)
JP (2) JP3672575B2 (enrdf_load_stackoverflow)
KR (2) KR100425656B1 (enrdf_load_stackoverflow)
CN (3) CN1159300C (enrdf_load_stackoverflow)
AR (4) AR012946A1 (enrdf_load_stackoverflow)
AT (2) ATE237599T1 (enrdf_load_stackoverflow)
AU (2) AU725517B2 (enrdf_load_stackoverflow)
BR (2) BR9804947A (enrdf_load_stackoverflow)
CA (3) CA2614926C (enrdf_load_stackoverflow)
CO (2) CO4940452A1 (enrdf_load_stackoverflow)
CY (1) CY2007014I1 (enrdf_load_stackoverflow)
CZ (2) CZ292260B6 (enrdf_load_stackoverflow)
DE (3) DE69811500T2 (enrdf_load_stackoverflow)
DK (2) DK0994863T3 (enrdf_load_stackoverflow)
ES (2) ES2192779T3 (enrdf_load_stackoverflow)
FR (1) FR07C0037I2 (enrdf_load_stackoverflow)
HU (2) HU225153B1 (enrdf_load_stackoverflow)
ID (2) ID27660A (enrdf_load_stackoverflow)
IL (2) IL125732A (enrdf_load_stackoverflow)
LU (1) LU91345I2 (enrdf_load_stackoverflow)
MY (2) MY125854A (enrdf_load_stackoverflow)
NL (1) NL300284I2 (enrdf_load_stackoverflow)
NO (2) NO329314B1 (enrdf_load_stackoverflow)
NZ (2) NZ331371A (enrdf_load_stackoverflow)
PE (2) PE79799A1 (enrdf_load_stackoverflow)
PL (2) PL192114B1 (enrdf_load_stackoverflow)
PT (1) PT994864E (enrdf_load_stackoverflow)
RU (2) RU2198167C2 (enrdf_load_stackoverflow)
SI (2) SI0994864T1 (enrdf_load_stackoverflow)
SK (2) SK283734B6 (enrdf_load_stackoverflow)
TR (2) TR199801631T1 (enrdf_load_stackoverflow)
TW (2) TW403740B (enrdf_load_stackoverflow)
UY (1) UY25844A1 (enrdf_load_stackoverflow)
WO (2) WO1998056773A1 (enrdf_load_stackoverflow)
ZA (2) ZA984966B (enrdf_load_stackoverflow)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW403740B (en) 1997-06-10 2000-09-01 Novartis Ag Novel crystal modifications of the compound 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide
US7192962B2 (en) * 2002-05-31 2007-03-20 Schering Corporation Xanthine phosphodiesterase V inhibitor polymorphs
GB0507298D0 (en) 2005-04-11 2005-05-18 Novartis Ag Organic compounds
US7875284B2 (en) * 2006-03-10 2011-01-25 Cook Incorporated Methods of manufacturing and modifying taxane coatings for implantable medical devices
US20090069390A1 (en) * 2007-09-12 2009-03-12 Protia, Llc Deuterium-enriched rufinamide
CA2736703A1 (en) 2008-10-13 2010-04-22 Cipla Limited Process for the preparation of rufinamide
CN101768124B (zh) * 2008-12-30 2012-01-04 北京本草天源药物研究院 一种药物晶体及其制备方法和用途
IT1395736B1 (it) * 2009-08-04 2012-10-19 Dipharma Francis Srl Forme cristalline di rufinamide
AU2010290049B2 (en) * 2009-09-04 2013-09-19 Tactical Therapeutics, Inc Novel compositions and processes for preparing 5-amino or substituted amino 1,2,3-triazoles and triazole orotate formulations
ES2498267T3 (es) 2010-04-30 2014-09-24 Laboratorios Lesvi, S.L. Procedimiento mejorado para la preparación de un intermedio de rufinamida
EP2465853A1 (en) * 2010-12-14 2012-06-20 Laboratorios Lesvi, S.L. Polymorph of rufinamide and process for obtaining it
ITMI20110718A1 (it) 2011-04-29 2012-10-30 Dipharma Francis Srl Procedimento per la purificazione di rufinamide
WO2014013511A2 (en) * 2012-07-20 2014-01-23 Hetero Research Foundation Rufinamide solid dispersion
WO2021099481A1 (en) 2019-11-20 2021-05-27 Medichem, S.A. Solid composition containing rufinamide

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3992378A (en) 1973-12-26 1976-11-16 Eli Lilly And Company Fluoralkyl quinoxadinediones
US4156734A (en) 1976-02-13 1979-05-29 Merck & Co., Inc. Antihypertensive compositions containing an aryl-substituted alanine azo and an arylhydrazino-propionic acid
GB1511195A (en) 1976-10-18 1978-05-17 Ici America Inc Triazole derivatives
US4536518A (en) 1979-11-01 1985-08-20 Pfizer Inc. Antidepressant derivatives of cis-4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine
US4346097A (en) * 1980-09-30 1982-08-24 Warner-Lambert Company Method for treating convulsions with pyrazole-4-carboxamide derivatives
FI834666A7 (fi) 1982-12-23 1984-06-24 Ciba Geigy Ag Foerfarande foer framstaellning av nya aralkyltriazolfoereningar.
US4789680A (en) * 1982-12-23 1988-12-06 Ciba-Geigy Corporation Aralkyltriazole compounds
US4511572A (en) * 1983-03-18 1985-04-16 The University Of Kentucky Research Foundation Triazoline anticonvulsant drugs
PH22568A (en) * 1985-04-18 1988-10-17 Ciba Geigy Ag Fluorinated benzyl triazoles and pharmaceutical compositions containing the same
CA2002864C (en) 1988-11-29 1999-11-16 Eddy J. E. Freyne (1h-azol-1-ylmethyl) substituted quinoline, quinazoline or quinoxaline derivatives
JPH02214504A (ja) 1989-02-15 1990-08-27 Nissan Chem Ind Ltd 光学活性キノキサリン化合物の晶析法
EP0484437A4 (en) 1989-07-27 1994-06-01 Searle & Co Renal-selective prodrugs for the treatment of hypertension
IL96507A0 (en) 1989-12-08 1991-08-16 Merck & Co Inc Nitrogen-containing spirocycles and pharmaceutical compositions containing them
AU656154B2 (en) 1990-11-06 1995-01-27 Astellas Pharma Inc. Fused pyrazine derivative
JP2753911B2 (ja) 1991-12-06 1998-05-20 キッセイ薬品工業株式会社 Ｎ−ｔｅｒｔ−ブチル−１−メチル−３，３−ジフェニルプロピルアミン塩酸塩の結晶多形およびその製造方法
DE4217952A1 (de) 1992-05-30 1993-12-02 Basf Ag Chinoxalin-2,3(1H,4H)-dione
US5248699A (en) 1992-08-13 1993-09-28 Pfizer Inc. Sertraline polymorph
US5631373A (en) 1993-11-05 1997-05-20 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University And The University Of Oregon, Eugene Oregon Alkyl, azido, alkoxy, and fluoro-substituted and fused quinoxalinediones
GB9418443D0 (en) 1994-09-13 1994-11-02 Pfizer Ltd Therapeutic agents
GB9419318D0 (en) 1994-09-24 1994-11-09 Pfizer Ltd Therapeutic agents
DK0812320T3 (da) 1995-02-22 2003-04-14 Aventis Pharma Ltd Amorft piretanid, polymorfe former deraf, fremgangsmåde til fremstilling deraf og deres anvendelse
EP0918758B1 (en) * 1996-07-11 2002-05-02 Novartis AG Process for preparing 1-substituted 4-cyano-1,2,3-triazoles
TW403740B (en) 1997-06-10 2000-09-01 Novartis Ag Novel crystal modifications of the compound 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide

Also Published As

Publication number Publication date
TR199801631T1 (xx) 1999-06-21
CA2256013A1 (en) 1998-12-17
US8076362B2 (en) 2011-12-13
US20030125568A1 (en) 2003-07-03
JP2000516258A (ja) 2000-12-05
FR07C0037I2 (enrdf_load_stackoverflow) 2008-05-16
PE79799A1 (es) 1999-09-03
CN1572789A (zh) 2005-02-02
HU226107B1 (en) 2008-04-28
RU2194041C2 (ru) 2002-12-10
EP0994863B1 (en) 2003-02-19
BR9804946A (pt) 1999-08-24
BR9804947A (pt) 1999-08-24
ES2192779T3 (es) 2003-10-16
PL330764A1 (en) 1999-05-24
IL125732A0 (en) 1999-04-11
HUP0000798A2 (hu) 2000-10-30
CY2007014I2 (el) 2009-11-04
AR012946A1 (es) 2000-11-22
PL191943B1 (pl) 2006-07-31
EP0994864A1 (en) 2000-04-26
US20040167186A1 (en) 2004-08-26
IL125733A (en) 2002-12-01
HUP0002113A2 (hu) 2001-02-28
ATE237599T1 (de) 2003-05-15
US20100310655A1 (en) 2010-12-09
DK0994864T3 (da) 2003-07-21
HK1028031A1 (en) 2001-02-02
EP0994863A1 (en) 2000-04-26
AU725528B2 (en) 2000-10-12
NO983667L (no) 1998-12-17
CA2256015A1 (en) 1998-12-17
HUP0002113A3 (en) 2002-09-30
KR19990087836A (ko) 1999-12-27
NO329315B1 (no) 2010-09-27
DE69811500T2 (de) 2004-04-01
SI0994863T1 (en) 2003-08-31
MY120156A (en) 2005-09-30
EP0994864B1 (en) 2003-04-16
AR012945A1 (es) 2000-11-22
CO4940448A1 (es) 2000-07-24
NZ331371A (en) 2000-08-25
US20010037029A1 (en) 2001-11-01
PT994864E (pt) 2003-07-31
AU8437298A (en) 1998-12-30
CO4940452A1 (es) 2000-07-24
HK1028241A1 (en) 2001-02-09
TW403740B (en) 2000-09-01
PL330798A1 (en) 1999-06-07
CA2256015C (en) 2008-06-03
NZ331370A (en) 2000-08-25
CA2614926A1 (en) 1998-12-17
US6455556B2 (en) 2002-09-24
LU91345I2 (fr) 2007-09-04
SK109398A3 (en) 1998-12-02
AU725517B2 (en) 2000-10-12
CZ292260B6 (cs) 2003-08-13
KR100409168B1 (ko) 2004-01-31
HUP0000798A3 (en) 2000-10-30
RU2198167C2 (ru) 2003-02-10
NO983666L (no) 1998-12-17
CN1217716A (zh) 1999-05-26
NL300284I1 (nl) 2007-10-01
NO983667D0 (no) 1998-08-11
AU8437198A (en) 1998-12-30
CY2007014I1 (el) 2009-11-04
CN1298708C (zh) 2007-02-07
TW526195B (en) 2003-04-01
HU225153B1 (en) 2006-07-28
AR061005A2 (es) 2008-07-30
IL125733A0 (en) 1999-04-11
SK109498A3 (en) 1998-12-02
NO329314B1 (no) 2010-09-27
SI0994864T1 (en) 2003-10-31
KR100425656B1 (ko) 2004-05-17
CA2614926C (en) 2010-02-09
KR19990087835A (ko) 1999-12-27
CA2256013C (en) 2007-10-16
ZA984967B (en) 1999-01-11
CN1159300C (zh) 2004-07-28
CZ253398A3 (cs) 1999-04-14
ID27660A (id) 2001-04-19
WO1998056772A1 (en) 1998-12-17
AR061004A2 (es) 2008-07-30
US20060116520A1 (en) 2006-06-01
DE122007000051I1 (de) 2007-11-08
DE69813560D1 (de) 2003-05-22
JP2000516259A (ja) 2000-12-05
HK1028242A1 (en) 2001-02-09
JP3672574B2 (ja) 2005-07-20
DE122007000051I2 (de) 2009-02-19
UY25844A1 (es) 2001-08-27
PE80999A1 (es) 1999-09-06
CZ253498A3 (cs) 1999-04-14
US6740669B1 (en) 2004-05-25
TR199801630T1 (xx) 1999-06-21
SK283734B6 (sk) 2003-12-02
WO1998056773A1 (en) 1998-12-17
CN1259127A (zh) 2000-07-05
US7750028B2 (en) 2010-07-06
NO983666D0 (no) 1998-08-11
LU91345I9 (enrdf_load_stackoverflow) 2018-12-31
FR07C0037I1 (enrdf_load_stackoverflow) 2007-08-17
DE69813560T2 (de) 2004-02-05
PL192114B1 (pl) 2006-08-31
NL300284I2 (nl) 2007-11-01
ID21014A (id) 1999-04-08
SK283685B6 (sk) 2003-12-02
ES2197485T3 (es) 2004-01-01
DE69811500D1 (de) 2003-03-27
CN1132820C (zh) 2003-12-31
CZ292481B6 (cs) 2003-09-17
ATE232852T1 (de) 2003-03-15
ZA984966B (en) 1999-01-11
MY125854A (en) 2006-08-30
JP3672575B2 (ja) 2005-07-20
IL125732A (en) 2002-12-01

Similar Documents

Publication Publication Date Title
NL300284I1 (nl) Kristalmodificatie van 1-(2,6-difluorbenzyl)1H-1,2,3-triazool-4-carboxamide en de toepassing daarvanals anti-epilepticum.
NO993522D0 (no) 4-(3-heterocyclyl-1-benzoyl)pyrazoler og anvendelse derav som herbisider
NO993646D0 (no) Tiazol benzensulfonamider som <beta>3-agonister for behandling av diabetes og fedme
DZ2936A1 (fr) Composition nouvelle à libération modifiée pour letraitement du diabète.
NO20000996D0 (no) Kombinasjonsterapi omfattende atorvastatin og et antihypertensivt middel
NO986024L (no) Substituerte 3,5-difenyl-1,2,4-triazoler og deres anvendelse som farmas°ytiske metallchelatorer
NO20001914D0 (no) <alfa>-Aryl-N-alkylnitroner og farmasøytiske blandinger som inneholder slike
FI20080645L (fi) Alkalinen Bacillus-amylaasi
NO990296D0 (no) HPPD-genet og inhibitorer
DK0984960T3 (da) N-triazol-2-indolcarboxamider og deres anvendelse som CCK-A-agonister
NO20012727L (no) 3,4,5-trisubstituerte arylnitronforbindelser og farmasöytiske sammensetninger som inneholder samme
NO20004903L (no) C11 oksymyl og hydroksylaminoprostaglandiner anvendbare som FP-agonister
TR199501688A2 (tr) 6-£triazolil£3-(trifluorometil)fenil|metil|-2-kuinolinonlar ve kuinolinetionlar.
IT1303769B1 (it) Catalizzatore e suo impiego per la sintesi di polioli polieteri.
NO981253D0 (no) Forsterkende middel
NO932315D0 (no) Overflateaktivt middel, fremgangsmaate ved dets fremstilling og anvendelse
TH9801002100B (th) รูปแบบโครงสร้างผลึกดัดแปลงของ 1-(2,6-ไดฟลูออโรเบนซิล)-1h-1,2,3-ไตรอาโซล-4-คาร์บอกซาไมด์
FR2720276B1 (fr) Nouvelle utilisation thérapeutique des agents bétamimétiques et médicament en contenant.
AU2003232809A1 (en) Use of bleaching catalyst combinations and bleaching agent compositions containing them
ITGE940093A0 (it) Preservativo con segnalazione di eventuale rottura.
IT237481Y1 (it) Aggiuntivi intercambiabili e ribaltabili per occhiali
DK1218351T3 (da) Nitroimidazolderivat og billeddiagnostisk middel indeholdende dette
KR950030687U (ko) 좌우 겸용으로 사용할 수 있는 경첩
DK0777491T3 (da) Anvendelse af smagsneutralt, hydrolyseret kollagen og middel indeholdende samme
ITMI950622A0 (it) Eteri di 5-(solfamoilmetil/carbamoilmetil)-cicloesenonossime